Lv41
530 积分 2022-08-25 加入
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
1小时前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
Alport syndrome: an update
1个月前
已完结
Alport Syndrome
1个月前
已关闭
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
1个月前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
1个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
1个月前
已完结
A retrospective study to investigate the risk factors for gestational diabetes mellitus and its impact on maternal and neonatal outcomes
2个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
2个月前
已完结
A cereblon-based glue degrader of NEK7 regulates NLRP3 inflammasome in a context-dependent manner
2个月前
已完结
皖公网安备34019202002308
